Tumour‐associated antigens (TAA), tumour‐specific antigens (TSA), NKG2D ligands, and stromal cell markers are typical CAR targets for CAR‐T and CAR‐NK therapy for breast cancer. This evidence concerns the gene KLRK1 and breast cancer.